Introduction {#sec1}
============

Coronavirus disease 2019 (COVID-19), caused by a novel coronavirus, SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), is the cause of a pandemic that has infected over 15,000,000 people worldwide with a mortality of ∼4% to date ([@bib200]). Two previously identified coronaviruses, SARS-CoV and MERS-CoV (Middle East respiratory syndrome coronavirus), caused severe pneumonia but, unlike SARS-CoV-2, exhibited only limited person-to-person spread, resulting in dramatically lower numbers of confirmed cases (∼8,100 and 2,500, respectively). Because COVID-19 has been associated with huge mortality and economic loss, efforts are underway to rapidly develop a vaccine, which will result in a safer and more expedient path to herd immunity. After vaccination, the goal will be not only protecting the vaccinated individual but also decreasing transmission by minimizing the number of susceptible individuals. Vaccine development is highly dependent on understanding the immune response to SARS-CoV-2, especially those components that are protective. However, the immune response to coronaviruses is not well understood, and specific aspects that are protective versus pathogenic are not well defined. While some aspects of SARS-CoV-2 immunity appear to be novel, much of the immune response parallels that observed in humans, domestic and companion non-human animals naturally infected with coronaviruses, and experimentally infected laboratory animals. In this review, we will focus on studies that described innate and adaptive immune responses in the setting of these non-SARS-CoV-2 infections, focusing on those studies that potentially provide insight into COVID-19 immunity and vaccine development in humans.

Coronavirus Biology {#sec1.1}
-------------------

*Coronaviridae* is a family of large (31 kb) single-stranded positive-sense RNA viruses that consist of viruses from four genera (alpha, beta, gamma, and delta coronavirus). SARS-CoV, MERS-CoV, and SARS-CoV-2 are all betacoronaviruses. Genomic coronavirus RNA is translated into a long polyprotein that contains proteins involved in RNA replication ([Figure 1](#fig1){ref-type="fig"} A). Structural proteins, which encompass the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins, and accessory proteins believed to be involved in immunoevasion, are translated from a nested set of subgenomic RNAs that have the same 5′ and 3′ ends ([Figure 1](#fig1){ref-type="fig"}B). A coronavirus protein, nonstructural protein 14 (nsp14), has proofreading capabilities and is critical for maintaining and is responsible for the increased replication fidelity of coronaviruses. This is especially important given the size of the coronavirus genome. Coronaviruses have an estimated error rate of 10^−6^ to 10^−7^ errors per nucleotide, which is much lower than that of smaller RNA viruses (error rates of 10^−3^-10^−5^) ([@bib175]).Figure 1Genomic Organization and Virion Structure(A) Schematic of the 30-kb SARS-CoV-2 genome. The first two-thirds of CoV genomes encode a polyprotein that is cleaved into constituent nonstructural proteins involved in replication and immune evasion, while the remaining one-third encodes the four main structural proteins (S, E, M, and N), along with accessory proteins.(B) Schematic representation of a CoV virion. gRNA, genomic RNA.

Animal Coronaviruses {#sec1.2}
--------------------

Coronaviruses are known to cause a wide variety of mild and severe diseases in domestic and companion animals, including livestock such as chickens, pigs, and cattle, as well as companion animals such as cats and dogs ([Table 1](#tbl1){ref-type="table"} ). Because these coronaviruses have significant economic and psychological importance to humans, correlates of immunity have been investigated to guide development of protective vaccines against these pathogens.Table 1Summary of Discussed CoronavirusesVirusGenusHostTropismAvailable vaccine?IBV*Gammacoronavirus*chickenrespiratory, kidney, reproductive tractLAVs against several heterologous strains ([@bib28])TGEV*Alphacoronavirus*pigentericLAV, PRCV as natural vaccine ([@bib164])PRCV*Alphacoronavirus*pigrespiratorynoBCoV*Betacoronavirus*cattlerespiratory, entericenteric disease only; inactivated virus, LAV ([@bib162])FCoV/FIPV*Alphacoronavirus*catenteric (FCoV)Temperature-sensitive LAV ([@bib66]; [@bib73])systemic (FIP)MHV*Betacoronavirus*mousestrain dependent (enteric, hepatic, respiratory, CNS)noHCoV-229E*Alphacoronavirus*humanrespiratorynoHCoV-NL63*Alphacoronavirus*humanrespiratorynoHCoV-OC43*Betacoronavirus*humanrespiratorynoHCoV-HKU1*Betacoronavirus*humanrespiratorynoSARS-CoV*Betacoronavirus*humanrespiratoryno; multiple phase 1 trials ([@bib118]; [@bib125])MERS-CoV*Betacoronavirus*humanrespiratoryno; three recently concluded phase 1 trials ([@bib67]; [@bib110]; [@bib133])SARS-CoV-2*Betacoronavirus*humanrespiratoryno; several ongoing trials ([@bib202])[^1]

Infectious bronchitis virus (IBV), a chicken coronavirus, causes bronchitis and kidney and reproductive tract disease ([@bib29]). A number of vaccines, particularly live virus attenuated by passage in chicken eggs, generate neutralizing antibodies and have been successfully used for decades to protect flocks against IBV. Caveats are that protection provided by many of these vaccines is short-lived, with protective immunity waning after about 9 weeks ([@bib29]), and these vaccines afford poor protection from heterologous strains of IBV ([@bib94]). The strength of cross-protection between variants is predicted by differences in the S1 subunit of the S protein, the site of most neutralizing antibody epitopes ([@bib30]). Of note for live attenuated vaccine strategies, high rates of recombination and frequent exposure of chickens to multiple vaccine and field IBV strains can contribute to the generation of novel virus strains and reversion to virulence ([@bib95]; [@bib96]; [@bib214]). S1 and the N protein contain CD8 T cell epitopes, which are known to confer protection, though little is known about the longevity of the T cell response to IBV or their relevance in vaccine-mediated immunity ([@bib51]).

Transmissible gastroenteritis virus (TGEV) is an enteropathic and highly contagious coronavirus that causes mild disease in adult animals but is nearly always fatal in piglets under 2 weeks of age, causing significant economic burden ([@bib164]). As such, a substantive portion of vaccine and immunity research has focused on the generation of immunoglobulin A (IgA) responses in sows, which confer passive lactogenic immunity to suckling pigs via colostrum or milk ([@bib39]; [@bib163]). T cell responses are correlated with the generation of lactogenic immunity in immunized sows, highlighting the importance of a cellular response ([@bib6]; [@bib142]). While various live attenuated vaccines have been used to immunize sows, these vaccines do not induce as strong an IgA response as infection with virulent TGEV and are thus less protective to newborn piglets ([@bib164]). Interestingly, the decline of TGEV incidence worldwide was correlated with the emergence of the closely related porcine respiratory coronavirus (PRCV) in 1983 ([@bib169]). PRCV, which generally causes subclinical to mild respiratory infections, is an S protein deletion mutant of TGEV. This roughly 200-amino-acid deletion in the N-terminal region of the S protein results in a shift of tropism from the enteric and respiratory tracts to only the respiratory tract ([@bib165]). Because this virus provides protection against TGEV infection, including in newborn piglets, it represents a natural TGEV vaccine ([@bib20]; [@bib195]). Interesting and perhaps relevant for COVID-19 immunity, IgA-mediated mucosal immunity following PRCV infection wanes over time, requiring reinfection or reimmunization prior to farrowing to produce protective lactogenic immunity ([@bib23]; [@bib194]).

Similar features have also been observed in cattle infected with bovine coronavirus (BCoV), which causes respiratory and enteric disease. Reinfection is commonly observed in animals with measurable antibody titers, with concomitant virus shedding from the respiratory tract. Of note, disease was mitigated in duration in animals with high IgA titers prior to infection ([@bib43]; [@bib84]). This recurrent theme of waning immunity and need for periodic boosts following initial infection or vaccination is relevant to our understanding of human respiratory coronaviruses and has implications for vaccine strategies against these viruses, especially SARS-CoV-2, in humans.

Feline infectious peritonitis virus (FIPV), a highly lethal feline coronavirus (FCoV), is thought to arise from mutations in the S protein during persistent infection with otherwise mild enteric strains of FCoV, resulting in a shift in tropism from intestinal epithelial cells to macrophages that allows systemic spread of the virus ([@bib161]). FIPV results in lymphopenia and severe serositis and is uniformly fatal. Antibody-dependent enhancement (ADE), a phenomenon in which virus-specific antibodies potentiate infection via Fc or complement-receptor-mediated uptake of infectious virus into myeloid cells, has been observed after vaccination against FIPV. This development of ADE reflects the macrophage tropism of FIPV and complicates vaccine development ([@bib189]; [@bib193]). ADE in the context of FIPV vaccination raises concerns about the same phenomenon occurring after SARS-CoV-2 vaccination, but ADE has not been described in any other coronavirus infection *in vivo*.

In addition, the most extensively studied coronavirus is mouse hepatitis virus (MHV), the prototypical laboratory coronavirus, which causes a wide variety of respiratory, enteric, neurological, and hepatic disease in susceptible rodents ([@bib13]). Some strains, such as the neurotropic JHMV or the neurotropic and hepatotropic MHV-A59, cause immune-mediated demyelination as a consequence of viral clearance ([@bib15]; [@bib191]). The immune responses to these neurotropic coronaviruses are among the most-studied aspects of coronavirus immunology, as these central nervous system (CNS) infections require an exquisite balance between immune activation to clear virus and suppression to prevent immunopathology. A crucial aspect of the immune response to these viruses is type I interferon (IFN), as mice lacking the type I IFN receptor (IFNAR) rapidly succumb to strains and doses of MHV that would ordinarily be sublethal or even nonpathogenic ([@bib92]; [@bib101]; [@bib160]). Type I IFN is produced both by macrophages or microglia and plasmacytoid dendritic cells (pDCs) in these infections, and signals through LysM^+^ macrophages and CD11c^+^ dendritic cells (DCs) for protection ([@bib32]; [@bib160]).

Virus-specific CD4^+^ and CD8^+^ T cell responses are necessary to clear CNS infection with JHMV ([@bib166]; [@bib196]); however, these same virus-specific T cell responses are pathogenic and mediate myelin destruction ([@bib4]; [@bib27]; [@bib203]). The role of type II IFN in T cells in protection and pathogenesis differs between CD4^+^ and CD8^+^ T cells, as IFN-γ produced by CD4^+^ T cells is protective against demyelination, whereas that produced by CD8^+^ T cells, while critical for viral clearance, contributes to demyelination ([@bib14]; [@bib148]; [@bib149]). Adding further to the complexity of the role of T cells in balancing viral clearance and immunopathogenesis, some subsets of these T cells, including T regulatory (Treg) cells and interleukin-10 (IL-10)-producing CD8^+^ T cells, are necessary for protection against excessive immune responses in the CNS ([@bib5]; [@bib33]; [@bib185]). Interestingly, virus-specific Treg cells targeting the same immunodominant epitope as effector T cells are particularly critical for suppressing immunopathology ([@bib217], [@bib220]). Of particular relevance to SARS-CoV-2 and other highly pathogenic human coronaviruses, T cells are essential to prevent cytokine storm in MHV-A59 via tempering the innate immune response in both a Treg and non-Treg cell-dependent manner ([@bib104]).

In addition to T cells, a virus-specific antibody response is required to prevent recrudescence after initial virus clearance, and passively transferred antibodies against MHV are protective against subsequent infection ([@bib119]; [@bib126]; [@bib154]). Neutralizing antibodies are also thought to play a key role in preventing CD8^+^ T cell escape, a feature of some persistent MHV infections ([@bib22]; [@bib48]; [@bib54]). An immunopathogenic role for infiltrating monocytes and macrophages, which are found at high numbers in demyelinating lesions, has also been implicated ([@bib184]). The role for these myeloid cells in demyelination is further supported by the finding that in *Rag1* ^−/−^ mice, expression of a macrophage chemoattractant (CCL2) encoded by recombinant virus is sufficient to mediate demyelination ([@bib103]).

Together, these studies of coronavirus infections of domestic and companion animals and experimentally infected animals illustrate the waning nature of the immune response, the requirement for both T cell and antibody responses for protection, and the fine balance between protective and pathogenic immune responses, which may all be relevant for understanding SARS-CoV-2 immunity.

Human Common Cold Coronaviruses {#sec1.3}
-------------------------------

The first human coronaviruses were isolated in the 1960s from nasopharyngeal samples of individuals experiencing common colds ([@bib128]; [@bib188]). These viruses were found to be morphologically similar to IBV and ultimately classified as coronaviruses. Four strains of these common cold coronaviruses are known to circulate globally, HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1, the latter two of which were discovered following heightened attention on human coronaviruses in the aftermath of the SARS epidemic ([@bib68]; [@bib86]; [@bib199]). Together, these coronaviruses are thought to cause ∼15% of common colds, and it has been estimated that ≥90% of adults have serum antibodies against these four viruses ([@bib74]; [@bib147]). Because these coronaviruses are the closest to SARS-CoV-2 in transmissibility and ability to replicate in the nasopharyngeal tract, albeit without the same predilection for severe lower respiratory tract disease, studies of the immune responses to these viruses may be of particular relevance to the current pandemic ([Figure 2](#fig2){ref-type="fig"} A; [@bib57]; [@bib179]).Figure 2Human Coronavirus Tropism and Longevity of Immune ResponsesSchematic depicting sites of replication of human coronaviruses (A) and schematic of longevity of immune responses to common cold coronaviruses, SARS-CoV, and MERS-CoV (B) (not drawn to scale). Data not available for antibody longevity in patients following mild disease caused by SARS-CoV.

The majority of our understanding of immunity against these viruses comes from experimental infections of volunteers with HCoV-229E or HCoV-OC43, as well as longitudinal serological surveys monitoring respiratory infections. These volunteer studies demonstrated that reinfection with a homologous virus can occur even when measurable titers of neutralizing antibodies are present in serum prior to infection, though there was an inverse correlation between antibody titer and likelihood of symptomatic infection ([@bib19]). Similar to studies of animal coronaviruses, antibody titers in volunteers had waned substantially 1 year after initial infection and many could be reinfected and shed virus, though these secondary infections did not cause clinical symptoms ([Figure 2](#fig2){ref-type="fig"}B; [@bib24]). Large serological surveys of natural infections with HCoV-229E and HCoV-OC43 have revealed similar trends of reinfection and patterns of waning and rising antibody titers, with estimates of anywhere between 30% and 80% of infections with HCoV-229E or HCoV-OC43 representing reinfections based on pre-infection antibody titers ([@bib85]; [@bib134]; [@bib168]). It should be noted that in all of these studies, serum antibody titers are measured. In other experimental respiratory virus infections, levels of mucosal antibody appear to be more relevant for establishing the likelihood of reinfection ([@bib79]; [@bib174]). Measurements of mucosal antibodies in COVID-19 patients will be critical for fully determining the likelihood of developing clinical disease after primary infection or vaccination. Reinforcing this notion of frequent reinfections with community-acquired respiratory coronaviruses, a recent longitudinal survey of 196 individuals using qRT-PCR-based detection of viral genetic material found that over an 18-month period, 12 of these individuals became reinfected with the same coronavirus at least once, with a mean of 37 weeks between positive tests ([@bib170]). In terms of therapeutic interventions, intranasal administration of recombinant IFN-α prior to infection protected against experimental infection, resulting in reduced viral loads and diminished incidence and severity of symptoms ([@bib231]). Early IFN-α treatment is thus likely to induce an antiviral state independent of the presence of optimal antivirus antibody and T cell responses.

SARS-CoV {#sec1.4}
--------

Beginning in Guangdong Province in China in November 2002, SARS-CoV, the causative agent of SARS, infected an estimated 8,098 people with a near 10% mortality rate until being declared contained by the World Health Organization (WHO) in 2003 ([@bib146]). This epidemic caused substantial global concern and sparked interest in coronavirus research. Relative to the common cold coronaviruses and SARS-CoV-2, SARS-CoV was significantly less transmissible and, despite worldwide dissemination, predominantly spread within healthcare settings and among households, with no evidence of asymptomatic transmission ([@bib144]).

SARS-CoV, like SARS-CoV-2, caused severe pulmonary pathology, manifested by edema, hyaline membrane formation, infiltration of inflammatory cells (including lymphocytes and macrophages in the alveoli and interstitium), and epithelial denudation ([@bib113]; [@bib138]). This pulmonary disease progressed to acute respiratory distress syndrome (ARDS), particularly in older individuals and those with underlying conditions ([@bib115]). Vasculitis, lymphopenia, spleen and lymph node atrophy, and virus presence in several tissues, including the blood, brain, spleen, and other tissues, were observed. Similar features are shared with COVID-19 ([@bib58]; [@bib77]; [@bib150]). While viral load began to decline around day 10 post-onset, clinical disease worsened in many patients around this time, suggesting potential immunopathology, rather than excessive viral replication, as the cause of clinical progression ([@bib145]). SARS-CoV, like SARS-CoV-2, uses angiotensin-converting enzyme 2 (ACE2) as its receptor for entry into the cell and primarily infects airway and alveolar epithelial cells ([Figure 2](#fig2){ref-type="fig"}A; [@bib82]; [@bib228]). Some studies suggested that the use of ACE2 as the viral receptor contributed directly to the virulence and pathology of SARS-CoV, as ACE2, a regulator of renin-angiotensin signaling, is downregulated upon entry and this inhibition can lead to enhanced lung pathology ([@bib91]; [@bib111]). Downregulation of ACE2 has been observed in mice infected with influenza A virus (IAV), which results in elevated serum angiotensin II compared to wild-type mice ([@bib205]; [@bib229]). In IAV-infected mice and patients, elevated serum angiotensin II is correlated with disease severity. Further, *Ace2* ^−/−^ mice develop more severe IAV-mediated disease than do their wild-type counterparts. These results support the notion that downregulation of ACE2 may contribute to SARS-CoV pathogenesis.

Studies of the immune response to SARS-CoV have consisted of both direct study of human SARS patients and animal models of SARS, including macaques, marmosets, and ferrets, as well as smaller animals, such as hamsters and particularly mice ([@bib75]). While mice are susceptible to infection with SARS-CoV, young mice develop no illness, and aged mice develop mild clinical disease ([@bib157]). In order to address this limitation, transgenic mice expressing the human ACE2 (hACE2) gene were developed; however, though they develop pulmonary disease, they also develop a lethal encephalitis ([@bib127]; [@bib186]). A different approach instead adapted SARS-CoV to mice by serially passaging the virus in mouse lungs. MA15, the first of these mouse-adapted SARS-CoV strains, caused severe pulmonary disease in young mice ([@bib158]). This virus had six coding mutations relative to the original virus, four of which were in located in ORF1 nonstructural proteins, one in the receptor-binding domain of the S protein, and one in the M protein. Subsequent experiments determined that the substitution in the receptor-binding domain of the S protein and, to a lesser extent, a second one in nsp9 contributed to the enhanced disease in mice relative to unadapted virus ([@bib70]).

### Innate Immune Responses {#sec1.4.1}

The cytokine response to SARS-CoV was frequently characterized by high-level production of pro-inflammatory chemokines and cytokines (e.g., CCL2, CCL3, CCL5, and CXCL10) and IL-6, tumor necrosis factor (TNF), and IL-8 production, all of which were further upregulated in patients with more severe disease ([@bib82]; [@bib99]; [@bib213]). Similar findings were also observed in SARS animal models and *in vitro*, both in human airway epithelial (HAE) cells and in human monocyte-derived macrophages and DCs after infection ([@bib42]; [@bib112]; [@bib207]). Interestingly, while macrophages and DCs can be infected by SARS-CoV and produce cytokines following infection, replication is abortive in these cells. Of note, infected monocytes/macrophages and monocyte-derived DCs do not produce type I IFN, suggesting that SARS-CoV immune evasion strategies are effective in these cells ([@bib42]; [@bib112]; [@bib208]).

As is the case of other viruses, such as measles virus, influenza virus, dengue virus, and Ebola virus ([@bib72]), coronaviruses, including SARS-CoV, have developed numerous mechanisms to counter the type I IFN response, both via evasion and direct antagonism of IFN signaling. Evasion of sensors of viral double-stranded RNA (dsRNA), including Mda5, RIG-I, and mitochondrial antiviral signaling protein (MAVS), is mediated by an array of mechanisms, including 2′-O-methylation of the 5′ viral mRNA cap by nsp16 ([@bib130]; [@bib230]), as well as endoribonuclease degradation of viral RNAs and selective RNA packaging mediated by nsp15 ([@bib11]; [@bib56]; [@bib108]). Other coronavirus proteins mediate inhibition of pattern recognition receptors or IFN production and signaling pathway molecules, reflecting an extensive array of mechanisms of immune evasion ([@bib65]; [@bib69]; [@bib88]; [@bib224]). Despite these immune evasion strategies, it has been shown that both primary human and mouse plasmacytoid DCs are capable of inducing a type I IFN response after SARS-CoV infection in a manner dependent on TLR7, which detects single-stranded RNA ([@bib31]; [@bib37]).

The type I IFN response in SARS patients was observed to be dysregulated in patients that experienced adverse outcomes and severe disease, with one report finding that IFN responses persisted significantly longer than in those patients who went on to recover, and were accompanied by the lack of a protective antivirus neutralizing antibody response ([@bib25]). Other reports did not describe this persistent IFN expression and instead found a poor IFN response relative to other respiratory viruses, a pattern that seems to be reflected in patients infected with SARS-CoV-2 ([@bib18]; [@bib155]). A pathogenic role for dysregulated IFN signaling is reflected in mouse studies of SARS-CoV. While pre-infection or early treatment with recombinant IFN-β or poly(I:C) to induce a type I IFN response resulted in complete protection from lethal disease, administration of IFN-β to mice at the peak of SARS-CoV replication led to delayed viral clearance and enhanced lethality rather than protection ([@bib37], [@bib38]; [@bib219]). This delayed IFN-enhanced disease was characterized by T cell apoptosis and elevated inflammatory monocyte and macrophage accumulation in the lungs, with production of inflammatory cytokines such as IL-6, CCL2, and TNF. Antibody-mediated depletion of these inflammatory monocytes and macrophages was fully protective against lethality, suggesting that these cells were responsible for significant immunopathology. Together, these data suggest a role for dysregulated IFN signaling in the immunopathogenesis of SARS-CoV and other coronaviruses.

### Adaptive Immune Responses {#sec1.4.2}

The antibody response to SARS-CoV is characterized by seroconversion as early as 4 days and generally ∼10--16 days post-onset, with titers peaking ∼15--20 days post-infection ([@bib87]; [@bib114]; [@bib204]). Several neutralizing antibody epitopes, predominantly against the S1 and S2 subunits of the S protein, and particularly the receptor binding domain (RBD) in the S1 subunit, have been identified ([@bib21]; [@bib226]). While antibodies against other structural proteins have been observed, these are largely non-neutralizing ([@bib2]; [@bib151]). A positive correlation between N- and S-protein-specific serum antibody titers and recovery from SARS-CoV was observed, and passive transfer of neutralizing antibodies was found to prevent replication in mouse models of SARS ([@bib16]; [@bib176]; [@bib212]). However, these antibody responses have been found to lack longevity. While serum antibody titers remain high for the first 2 years after infection, by 3 years post-infection, only 55% of patients tested had detectable IgG responses to SARS-CoV proteins, and by 6 years post-infection, no detectable memory B cell responses remained in the periphery ([@bib182]; [@bib204]). These data suggest that antibody responses to SARS-CoV, like those to common cold coronaviruses, wane significantly with time ([Figure 2](#fig2){ref-type="fig"}B). However, a recent study suggests that as late as 13 years post-infection, low levels of IgG against whole SARS-CoV could be detected some survivors, suggesting variability in the longevity of the antibody response ([@bib78]). Further, a meta-analysis convalescent plasma therapy during the SARS epidemic demonstrated some efficacy, highlighting the importance of the humoral response to SARS-CoV ([@bib124]).

In contrast to the poor longevity of the antibody response to SARS-CoV, the memory T cell response has been reported to have significant longevity in patients ([Figure 2](#fig2){ref-type="fig"}B), with CD4 and CD8 T cell responses in the blood identified by ELISpot at 4 and 6 years after infection in 70%--100% of patients, including those with no identifiable memory B cell responses in the blood ([@bib64]; [@bib139]; [@bib182]). These T cells were frequently polyfunctional, expressing IFN-γ, TNF, and other cytokines. Others have identified positive CD8 T cell responses as late as 11 years post-infection ([@bib137]). The duration of this memory T cell response was positively correlated, at least in part, with disease severity ([@bib182]). A number of T cell epitopes have been identified, with most found in the S, N, and M proteins ([@bib121]). While the longevity and specificity of the T cell response in human studies have been well studied, the kinetics of the T cell response during acute infection and the correlates of protection are less well understood. Lymphopenia was a commonly observed phenotype in SARS patients during acute disease, and T cell activation was also found to be suppressed, particularly in patients with severe disease ([@bib26]; [@bib83]; [@bib210]). Additionally, increased T helper 2 (Th2) cytokine expression correlate with poor outcomes in patients, a finding also supported in mouse studies of SARS-CoV ([@bib116]; [@bib141]).

Because of the general lack of human data regarding T cell kinetics and function during acute coronavirus infections, much of our understanding of their role comes from studies of mice. Zhao et al. found that suboptimal T cell responses result from an impairment of respiratory DC migration from the lungs to the lymph nodes ([@bib215]). This inhibition of DC migration was mediated, at least in part, by inhibitory alveolar macrophages, as depletion of these cells prior to infection resulted in enhanced T cell responses, viral clearance, and survival in mice. Aging is thought to play a significant role in this process, as expression of prostaglandin D2 (PGD~2~) and an upstream phospholipase (PLA~2~G2D) increase with age and are strongly correlated with this migration defect and suboptimal T cell response. Inhibition or depletion of these factors reverse these age-related impairments ([@bib190]; [@bib218]). PGD~2~ signaling through its receptor on DCs may contribute to the exacerbated disease and enhanced mortality observed with age in the SARS epidemic. Infected HAE cells have also been observed to produce cytokines, particularly IL-6 and IL-8, that inhibit priming of naive T cells by DCs ([@bib209]).

Further, T cells alone are sufficient to partly control SARS-CoV in mice, as adoptive transfer of activated T cells into *Rag1* ^−/−^ mice lacking T cell responses ameliorated disease and conferred significant protection and viral clearance. Depletion of CD4 T cells during SARS-CoV infection resulted in impaired viral clearance and reduced neutralizing antibody titers ([@bib41]; [@bib216]). Immunization with vaccinia encoding CD4 or CD8 T cell epitopes or DCs coated with these peptides prior to infection with SARS-CoV resulted in significant protection from SARS-CoV lethality ([@bib36]; [@bib216]). Intranasal immunization of mice with Venezuelan equine encephalitis replicon particles (VRPs) encoding an N-protein-specific CD4 T cell epitope resulted in the generation of an airway memory T cell response that conferred complete protection from lethality and reduced pulmonary edema upon SARS-CoV infection and resulted in enhanced DC and CD8 T cell responses in an IFN-γ-dependent manner, highlighting the role of type II IFN in the lungs ([@bib222]). However, others have observed enhanced immunopathology and eosinophilic infiltrates in the lungs in mice immunized peripherally with VRP-N and challenged with SARS-CoV, demonstrating the importance of the route of immunization in protection ([@bib55]). Together, these data highlight the important roles that both the humoral and cellular response to SARS-CoV have in controlling disease and guide vaccine studies.

MERS-CoV {#sec1.5}
--------

MERS-CoV was first identified in 2012 and to date has resulted in ∼2,500 confirmed infections, with a mortality rate of ∼35% ([@bib201]; [@bib211]). Like SARS-CoV, this virus is significantly less transmissible than the common cold coronaviruses or SARS-CoV-2, with all cases occurring on the Arabian Peninsula or travelers from this region with local transmission. The most notable outbreak occurred in South Korea, in which the index case had recently returned from the Arabian Peninsula ([@bib44]). Primary infections are believed to occur via camel-to-human transmission, as the virus circulates widely in dromedary camels throughout Asia and Africa ([@bib45]; [@bib102]; [@bib225]). Secondary infections largely occur in healthcare and household settings ([@bib60]; [@bib129]). In severe cases, MERS manifests clinically as pneumonia than can rapidly progress to ARDS and multiorgan failure ([@bib7]). While only two autopsies have been performed, diffuse alveolar damage with hyaline membrane formation in the lungs and alveolar edema was observed ([@bib3]; [@bib136]). MERS-CoV predominantly infects cells of the respiratory tract, using dipeptidyl peptidase 4 (DPP4) as its receptor for cell entry, which is highly expressed on airway epithelial cells and some hematopoietic cells ([Figure 2](#fig2){ref-type="fig"}A; [@bib153]).

As in SARS, study of the human immune response is limited. This has led to the use of MERS-CoV-susceptible animal models, such as macaques and marmosets, and the development of mouse models that express humanized DPP4, as well as mouse-adapted MERS-CoV, to facilitate study of the immune response to the virus ([@bib49]; [@bib63]; [@bib117]; [@bib198]; [@bib221]).

### Innate Immune Responses {#sec1.5.1}

The innate immune response in severe MERS is characterized by elevated levels of pro-inflammatory cytokines in the blood, particularly IL-6 and CXCL10, along with IL-8, CCL5, and IFN-α ([@bib105]; [@bib132]). These elevated cytokines correlated with elevated numbers of neutrophils and macrophages and lymphopenia in peripheral blood mononuclear cell (PBMC) samples, suggesting that they contribute to immunopathology. Unlike SARS-CoV, which only abortively infected macrophages and DCs, MERS-CoV replicates in human monocyte-derived macrophages and DCs, causing elevated production of these cytokines relative to SARS-CoV in these cells ([@bib46]; [@bib187]; [@bib227]). Infection of HAE cells also resulted in production of pro-inflammatory cytokines, as well as downregulation of major histocompatibility complex (MHC) class I and II molecules, in part via epigenetic modulation of MHC class I components ([@bib100]; [@bib131]).

MERS infection of myeloid cells or HAEs did not result in type I IFN production, again reflecting the ability of coronaviruses to evade viral RNA sensing and antagonize the IFN response. Similar to SARS-CoV, however, infection of human pDCs resulted in abortive infection with expression of both type I and type III IFNs in a TLR7-mediated manner ([@bib167]). In experimentally infected macaques, early treatment with IFN-α (beginning 8 h post-infection) and ribavirin resulted in reduced pathology and viral load ([@bib62]). Similar to experiments with SARS-CoV, treatment of mice with recombinant IFN-β was protective when provided prior to the peak of viral replication (1 day post-infection), whereas delaying treatment until the peak of viral replication (2--4 days post-infection) resulted in elevated viral load, an increase in neutrophils and inflammatory monocytes and macrophages in the lungs, and enhanced lethality ([@bib38]). Clinical trials of recombinant IFNs in combination with ribavirin, a nucleoside inhibitor and antiviral, have demonstrated no changes in 28- and 90-day survival rates or kinetics of viral clearance ([@bib8]; [@bib140]), though clinical trials of IFN in combination with antiviral protease inhibitors (lopinavir and ritonavir) are ongoing ([@bib9]). Taken together, these data reflect a role for dysregulation of the innate immune response in the pathogenesis of MERS-CoV similar to that observed with SARS-CoV.

### Adaptive Immune Responses {#sec1.5.2}

While most patients showed seroconversion ∼2--3 weeks post-onset of disease, absent or delayed antibody responses were strongly associated with severe or fatal disease ([@bib52]; [@bib143]). Neutralizing antibodies identified in human patients, as well as convalescent patient sera, showed both prophylactic and therapeutic protection in mice ([@bib53]; [@bib223]). However, while these antibodies had a protective effect in mice, MERS-CoV clearance was demonstrated in mice lacking B cells, showing that antibodies are not necessary to clear acute infection ([@bib221]). Because MERS-CoV frequently crosses from camels to infect humans, antibodies that allow neutralization of diverse camel strains of MERS-CoV, as well as antibodies or combinations of antibodies that prevent antibody escape, have been identified ([@bib180]; [@bib183]; [@bib192]). While MERS-CoV-specific antibody responses persist for at least 2 years in patients who recovered from severe disease, responses are not detected or transient in patients with subclinical or mild disease, waning to low or undetectable levels by 2 years post-infection ([Figure 2](#fig2){ref-type="fig"}B; [@bib60]; [@bib223]).

The T cell response to MERS-CoV has been partially characterized. Despite lymphopenia in many patients, MERS-specific CD8 T cell response were observed in patients with severe disease, whereas CD4 T cell responses did not develop until convalescence ([@bib172]). It has been shown that activated T cells can be directly infected *ex vivo* with MERS-CoV, resulting in activation of apoptosis pathways, which could, along with the downregulation of MHC molecules in airway epithelial cells and dysregulated cytokine response, contribute to the lymphopenia observed in many patients ([@bib47]). Memory T cell responses in MERS survivors were polyfunctional, expressing both IFN-γ and TNF, consistent with greater protective ability. These responses could be detected in all patients as late as 2 years post-infection, including in patients with no detectable antibody response, suggesting that at least some immune memory remains intact despite transient antibody responses ([@bib223]). Further, T cell responses have been demonstrated to play critical protective roles in MERS-CoV infections of mice, as animals lacking T cells were incapable of clearing virus, resulting in persistent infection ([@bib221]). Intriguingly, immunization with a VRP encoding a SARS-CoV N protein CD4 T cell epitope resulted in some degree of cross-protection against MERS-CoV, resulting in reduced viral load ([@bib222]). This epitope is fairly well conserved between these two and related bat coronaviruses. It was observed that mice immunized with the MERS-CoV-specific epitope mediated some protection upon SARS-CoV infection, and the homologous epitope in a MERS-like bat coronavirus (HKU4) mediated protection against MERS-CoV challenge. Despite these protective roles for T cells in MERS-CoV infection, others have found that depletion of CD8 T cells in a sublethal mouse model of MERS-CoV results in diminished lung pathology and clinical disease without impacting the viral titers, suggesting that these cells may also play a role in immunopathogenesis ([@bib50]).

While there are no currently licensed vaccines for MERS-CoV, three vaccine candidates, an adenovirus-vectored vaccine, a modified vaccinia Ankara-vectored vaccine, and a DNA vaccine, each of which encodes the full-length S protein of MERS-CoV, have recently concluded phase 1 clinical trials and were demonstrated safe and capable of inducing neutralizing antibodies and virus-specific T cells responses in participants ([@bib67]; [@bib110]; [@bib133]). However, consistent with the results from the natural infection, immune responses, especially neutralizing antibody titers, had waned by 1 year after vaccination.

The Next Steps Forward {#sec1.6}
----------------------

One can draw several conclusions relevant to our understanding of COVID-19 immunity from prior coronavirus studies. First, while less important for vaccine strategies, it is apparent from studies with MHV, as well as SARS-CoV and MERS-CoV, that an early type I IFN response is critical for protection from severe disease and preventing an exacerbated or aberrant pro-inflammatory cytokine response. However, coronaviruses engage in various immune evasion strategies that successfully prevent detection by pattern recognition receptors or inhibit IFN signaling pathways, resulting in either absent or delayed and dysregulated IFN responses that contribute to pathogenesis, rather than protection. Reflecting this, studies of SARS-CoV-2 have shown that the virus is sensitive to IFN pretreatment *in vitro*, but patients have impaired IFN responses with low levels of IFN production or signaling ([@bib18]; [@bib80]; [@bib122]). The cytokine and chemokine response in patients has also been found to be dysregulated in patients with impaired IFN responses, particularly those with severe disease, with many of the elevated pro-inflammatory cytokines and chemokines matching those seen in SARS and MERS, including CXCL10, CCL2, CCL3, IL-6, and TNF ([@bib40]; [@bib89]; [@bib206]).

Second, studies of animal and human coronaviruses indicate that both the humoral and cellular adaptive immune responses are important mediators of protection, and a vaccine should robustly induce both. Neutralizing antibody responses are protective in coronavirus infections and are thus a primary target for vaccine strategies. However, as described above, antibody responses to coronaviruses can wane rapidly following infection or immunization, allowing for potential reinfection, particularly in mild or subclinical disease such as those caused by the common cold coronaviruses or mild MERS. Because SARS-CoV-2 infection often presents with asymptomatic or mild disease similar to the common cold viruses ([@bib10]; [@bib17]), this is of particular concern, as it is possible that those cases will develop rapidly waning immunity relative to severe cases, potentially allowing for reinfection similar to the common cold coronaviruses. While seroconversion is observed in all COVID-19 patients 2--3 weeks post-symptom onset, early observations have suggested that antibody titers can wane significantly as early as 30--50 days post-symptom onset ([@bib1]; [@bib123]; [@bib156]). To date, while SARS-CoV-2 RNA has been detected after periods of negative testing, there is no available culture-based evidence confirming reinfection ([@bib109]). Together, these data suggest that vaccine strategies against SARS-CoV-2 could require boosting to maintain sufficient neutralizing antibody titers if the immune response is similar to that observed in mild disease. In contrast, based on our experience with MERS and SARS, it is probable that a more stable immune response will develop in patients with severe pneumonia.

Third, T cell responses are also sufficient for at least partial protection in many coronavirus infections and play a role in mitigating the exuberant innate immune responses involved in cytokine release syndromes. However, as in the case of SARS and MERS patients, COVID-19 patients develop lymphopenia, particularly those with severe disease, delaying the T cell response to the virus, though a virus-specific CD4 and CD8 T cell response is eventually mounted in most patients ([@bib76]; [@bib89]; [@bib181]). T cell responses to SARS-CoV and MERS-CoV have also been observed to have enhanced durability relative to neutralizing antibody responses and thus are crucial for longevity of immunity induced by vaccination. However, T cells have also been observed to play immunopathogenic roles in some coronavirus infections, including Th2-skewed responses to SARS-CoV. Defining and generating a protective T cell response, rather than a pathogenic Th2-driven response, will also be important for vaccine efficacy.

Another consideration for vaccination strategies is the generation of mucosal immunity, as studies of both animal coronaviruses and SARS-CoV and MERS-CoV have highlighted the importance of IgA-driven immune responses and localization of T cells to the respiratory tract and lungs. Reflecting this, preclinical animal studies of SARS-CoV and MERS-CoV vaccine candidates have found enhanced protection correlated with intranasal immunization relative to parenteral routes ([@bib97]; [@bib106]; [@bib222]).

Finally, on a cautionary note for vaccination, the potential for enhanced disease, in the forms of ADE or vaccine-associated enhancement of respiratory disease (VAERD), must be considered. As mentioned above, ADE has not been observed in any human coronavirus or, for the most part, in non-human coronaviruses. Viruses associated with ADE show a preferential tropism for macrophages, unlike human respiratory coronaviruses. As SARS-CoV-2 primarily infects the respiratory tract and lungs, a markedly different tropism than the macrophage-tropic FIPV, ADE is unlikely in our estimation. ADE has also never been observed in SARS or MERS, and sera from rats immunized with the receptor-binding domain of the SARS-CoV-2 S protein does not enhance viral entry into Fcgamma receptor-expressing cells, further suggesting that this is unlikely for SARS-CoV-2 ([@bib152]). VAERD, on the other hand, has some precedent in vaccination studies of animal models of SARS, including in non-human primates ([@bib120]) and mice immunized against a human SARS-CoV isolate and challenged with a heterologous strain of the virus ([@bib55]). These mouse studies also indicated that VAERD was most prominent in aged mice. While vaccines need to be carefully evaluated for evidence of VAERD, there is good reason to believe that proper vaccine and adjuvant formulation will minimize the risks of this problem yet still induce a protective immune response ([@bib93]). Critical will be to identify a vaccine strategy that elicits long-lasting immune responses.

Reaching these goals will require progress on several fronts. Much of our understanding of immune responses in the context of MERS and SARS resulted from studies of experimentally infected animals. Thus, the establishment of useful animal models of COVID-19 will be instrumental in understanding COVID-19 immunity. Taking cues from prior knowledge of SARS-CoV and MERS-CoV animal models, several of these models are currently being explored, including non-human primates, ferrets, hamsters, and mice. Each of these models presents unique advantages and disadvantages.

Infection of non-human primates, specifically macaques, results in mild clinical disease, virus replication in the respiratory tract, and pathological features such as pulmonary edema and hyaline membrane formation, features shared with COVID-19 ([@bib135]; [@bib159]). As non-human primates are our closest evolutionary relatives, these animals may provide the most relevant data for human pathogenesis, immunity, and preclinical therapy and vaccine safety and efficacy ([@bib35]; [@bib71]; [@bib197]). However, the limited availability and expense associated with non-human primate studies limit their potential for widespread use. The use of smaller, more abundant, and readily available animal models is thus of importance as well.

While ferrets are often used in studies of respiratory disease and infection ([@bib61]), infection with SARS-CoV-2 results in relatively low viral titers and a lack of symptoms other than elevated body temperature ([@bib107]; [@bib171]). Ferrets will be useful for transmission studies, because infection of ferrets results in transmission of SARS-CoV-2 to co-housed naive ferrets. Similarly, infection of hamsters results in transmission to naive animals, both with direct and indirect contact. Despite elevated viral genomic material relative to ferrets, clinical symptoms are limited to relatively mild weight loss and moderate-to-severe lung pathology ([@bib34]; [@bib90]; [@bib173]). These models will be best suited for study of SARS-CoV-2 transmission, particularly modeling asymptomatic or mild COVID-19 patient spread, as well as evaluation of vaccines and antiviral drugs.

Laboratory mice, due to their widespread availability, diverse array of reagents and tools for study, and past use as models for SARS-CoV and MERS-CoV, are of particular interest for studies of the immune response to SARS-CoV-2. While mice do not naturally support SARS-CoV-2 replication due to receptor incompatibility between the receptor-binding domain of the virus and mouse ACE2 ([@bib228]), several approaches are being used to render mice susceptible to SARS-CoV-2 infection, informed by similar mouse models of MERS and SARS. One such approach is the generation of transgenic mice expressing hACE2 under control of promoters that allow for expression in airway epithelial cells ([@bib12]; [@bib98]). This approach allows for infection of the respiratory tract and the development of mild lung pathology following infection; however, hACE2 may also be expressed in additional tissues, including the brain. Infection of the brain results in a lethal encephalitis, similar to results observed when hACE2-transgenic mice were infected with SARS-CoV ([@bib127]). While SARS-CoV-2 RNA has also been identified in the brains of COVID-19 patient autopsies ([@bib150]), the paucity of lung findings compared to the severe brain disease makes these mice not useful as models of the severe COVID-19 respiratory disease. Knockin (KI) mice, in which hACE2 replaces the mouse ACE2 gene rather than being randomly inserted into the genome, are also being developed. One such KI resulted in the expression of hACE2 in airways and in the development of pneumonia following infection; however, clinical disease was mild and restricted to aged mice ([@bib178]). Based on previous studies of hDPP4-KI mice, it is likely that passage through mouse lungs will be required for the generation of virulent SARS-CoV-2 that will provide a model for severe pneumonia ([@bib49]; [@bib117]). An alternative method to generate hACE2 mice uses transduction of with an adenoviral vector encoding for hACE2, a method also used for the generation of a mouse model of MERS ([@bib221]). Because vector is instilled intranasally, this results in expression of hACE2 exclusively in the respiratory tract of mice ([@bib81]; [@bib177]). Finally, another approach is to use reverse genetics to mutate residues in the receptor-binding domain, allowing for binding of the virus to mouse ACE2 and thereby facilitating viral entry into mouse cells. One such mouse-adapted virus, generated via targeted mutation without serial passage, is able to replicate in mice, though clinical disease was mild and observed primarily in aged mice ([@bib59]). As in the case of hDPP4-KI mice, further passage of this virus through mouse lungs will likely result in more virulent virus. Thus, it is probable that some combination of mouse-adapted virus and wild-type or hACE2-expressing mice will produce the most robust mouse models for severe COVID-19, and these models will complement other models of mild disease.

Critical Questions for COVID-19 Immunity {#sec1.7}
----------------------------------------

Several outstanding questions are crucial to address to understand whether prior infection confers protection upon subsequent reinfection and for informed development of vaccines. First, determining whether a neutralizing antibody and/or SARS-CoV-2-specific T cell response is sufficient to prevent clinical disease and transmission is critical. If so, it will also be important to determine the magnitude of the responses required to provide protection in order to inform both social measures and vaccine strategies that can limit spread. Second, it will be essential to perform longitudinal studies to establish the longevity of these protective adaptive immune responses following natural infection or vaccination. Proper and detailed longitudinal studies will require substantial investment of resources by governments, industry sources, non-governmental agencies, and others. Third, identifying factors that contribute to the dysregulated immune response and immunopathology in patients with severe disease could inform early therapeutic options to limit disease severity. A critical part of these endeavors will require identification of biomarkers that identify patients predisposed to severe disease so that they can be managed aggressively to prevent poor outcomes. Finally, it will be essential, as vaccines are introduced into widespread use, to not only assess efficacy against severe disease and ability to minimize transmission but also identify vaccine-enhanced disease so that vaccination is safe and widely accepted by the public.
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[^1]: IBV, infectious bronchitis virus; TGEV, transmissible gastroenteritis virus; PRCV, porcine respiratory coronavirus; BCoV, bovine coronavirus; FCoV, feline coronavirus; FIPV, feline infectious peritonitis virus; MHV, mouse hepatitis virus; HCoV, human coronavirus; SARS-CoV, severe acute respiratory syndrome coronavirus; MERS-CoV, Middle East respiratory syndrome coronavirus; CNS, central nervous system; LAV, live attenuated vaccine.
